Oxford Biomedica Regulatory News (OXB)

Oxford BioMedica Announces Option Agreement with GlaxoSmithKline

Oxford, UK - 18 December 2013: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announces that it has signed an option agreement with GlaxoSmithKline ("GSK") which grants GSK an option to a non-exclusive licence under Oxford BioMedica's LentiVector® platform technology patents for the development and commercialisation of up to six product candidates targeting rare orphan diseases. Financial terms were not disclosed.

In 2006, Oxford BioMedica previously granted GSK a non-exclusive licence to its LentiVector® platform technology patents for research purposes.

John Dawson, Chief Executive Officer of Oxford BioMedica, commented: "With a diverse pipeline of product candidates and a world-class reputation, GSK is a strong licensee of our LentiVector® platform technology patents."

- Ends -

Notes to editors

1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

2. LentiVector® gene delivery technology

Oxford BioMedica's LentiVector® gene delivery technology is one of the most advanced gene delivery systems currently available, which has many applications in product development and discovery research. It is the system of choice for gene-based treatments addressing chronic and inherited diseases. Oxford BioMedica has established a dominant intellectual property estate in the field of lentiviral-vector mediated gene delivery through its in-house research and from work conducted by the Company's co-founders at Oxford University.